Madrid, Spain – 29 August 2025: A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at moderate-to-high stroke risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in JAMA (The Journal of the American Medical Association).1
Explaining the rationale, AMALFI Chief Investigator, Professor Louise Bowman, from Oxford Population Health, United Kingdom, said: “AF is associated with an increased risk of stroke, but AF can be difficult to detect as it often occurs without symptoms and/or infrequently. Screening for AF has been proposed as a way to prevent strokes but many short or infrequent asymptomatic AF episodes may be missed. The advent of new monitoring technology has enabled longer-duration screening. The AMALFI trial was designed to assess the long-term efficacy of remote screening for asymptomatic AF in older individuals at increased risk of stroke using a 14-day continuous ECG monitoring patch.2”
In the investigator-initiated, parallel-arm unblinded randomised controlled AMALFI trial, eligible individuals were identified from 27 primary care practices in the UK via automated electronic health record searches. Participants were aged ≥65 years with a CHA2DS2VASc stroke risk score ≥3 for men or ≥4 for women. The key exclusion criterion was a previous diagnosis of AF or atrial flutter.
Participants were randomised 1:1 either to receive and return by postal mail an ECG patch monitor or to usual care (control). The primary outcome was the proportion of participants with the presence of AF in primary care records within 2.5 years after randomisation, which was analysed using an intention-to-treat approach.
A total of 5,040 individuals were randomised. At baseline, participants had a mean age of 78 years, 47% were female and 19% had a prior stroke or transient ischaemic attack.
There was a modest increase in AF diagnosis at 2.5 years with the ECG patch. A post-randomisation primary care record of AF was present in 6.8% of individuals in the intervention arm and 5.4% in the control arm (ratio of proportions 1.26; 95% confidence interval [CI] 1.02 to 1.57; p=0.03). Patch-detected AF burden was bimodally distributed, with 33% of cases having 100% burden (the entire monitoring period was spent in AF), while 55% had an AF burden <10%.
At 2.5 years, mean exposure to oral anticoagulation was 1.63 months in the intervention arm and 1.14 months in the control arm (difference 0.50 months; 95% CI 0.24 to 0.75; p<0.0001). Stroke occurred in 2.7% of participants in the intervention arm and 2.5% in the control arm (event rate ratio 1.08; 95% CI 0.76 to 1.53).
AMALFI Investigator, Doctor Rohan Wijesurendra, from Oxford Population Health, concluded: “Our trial shows that remote AF screening with an ECG patch monitor in older patients at moderate-to-high stroke risk leads to a modest increase in AF diagnosis and anticoagulation exposure. However, AF diagnosis unrelated to the patch occurred more commonly than anticipated and over half of the patch-detected AF burden was low burden (below 10%). This suggests that AF screening in this setting may have limited impact on stroke events; longer-term and cost-effectiveness analyses of AMALFI are planned and will provide more insight in due course.”
ENDS
Notes to editor
This press release accompanies both a presentation and an ESC press conference at
ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
Funding: Funding was provided by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre and the British Heart Foundation. iRhythm supported the study by providing Zio XT ambulatory monitoring patches, ECG analysis and cardiac technician data review at no charge.
Disclosures: Professor Bowman reports grants from National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, grants from British Heart Foundation, and non-financial support from iRhythm Technologies during the conduct of the study; grants from Novartis and grants from Novo Nordisk outside the submitted work. Doctor Wijesurendra reports grants from National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, grants from British Heart Foundation, and non-financial support from iRhythm Technologies during the conduct of the study.
References and notes:
1‘AMALFI: Active monitoring for atrial fibrillation’ presented during HOT LINE 1 on 29 August 2025 at 11:15 to 11:25 in Madrid (Main Auditorium) and simultaneously published in JAMA (The Journal of the American Medical Association)
2Wijesurendra R, Pessoa-Amorim G, Buck G, et al. Active Monitoring for AtriaL FIbrillation (AMALFI): rationale, protocol, and pilot for a pragmatic, randomized, controlled trial of remote screening for asymptomatic atrial fibrillation. Am Heart J. 2025;doi:10.1016/j.ahj.2025.07.004.
ESC Press Office
Tel: +33 661401884
Email: press@escardio.org
The hashtag for ESC Congress 2025 is #ESCCongress
Follow us on LinkedIn @European Society of Cardiology News
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
Journal
JAMA